

JENKINS  
WILSON  
& TAYLOR

patent attorneys

December 16, 2003



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 16, 2003.

*Patty Wilson*  
Patty Wilson  
Date of Signature: December 16, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/663,879 for  
IMIDAZOLINE RECEPTOR BINDING COMPOUNDS  
Our Ref. No. 421/60/10/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages) in duplicate; and
3. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. **50-0426**.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

*Arles A. Taylor, Jr.*

Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/ptw  
Enclosures

Customer No: **25297**

\* RICHARD E. JENKINS

\* JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY J. OLIVE

MICHAEL J. CROWLEY

\* CHRIS PERKINS, PH.D.

\*\* JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

OF COUNSEL  
SOROJINI BISWAS


\* LICENSED ONLY IN CA

\*\* LICENSED ONLY IN KY

tel 919.493.8000  
fax 919.419.0383

Jenkins, Wilson & Taylor, P.A.  
JenkinsWilsonTaylor.com

University Tower, Suite 1400 | 3100 Tower Boulevard | Durham, North Carolina 27707



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 16, 2003.

**PATENT**

Patty Wilson  
Patty Wilson  
Date of Signature December 16, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: 10/663,879                      Group Art Unit: Unknown

Serial No.: 10/663,879                      Examiner: Unknown

Filed: September 16, 2003                      Docket No.: 421/60/10/2

For: IMIDAZOLINE RECEPTOR BINDING COMPOUNDS

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Form PTO-1449 is attached hereto.

Copies of the cited documents are of record in the file history of U.S. Patent Application Serial No. 09/120,584 filed on July 22, 1998. The above-captioned application claims priority to U.S. Patent Application Serial No. 09/120,584 under 35 U.S.C. § 120, and as per 37 C.F.R. § 1.98, no copies of these cited documents are believed to be required.

Serial No.: 10/663,879


Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 12/16/2003

By:   
Arles A. Taylor, Jr.  
Registration No. 39,395

421/60/10/2      AAT/ptw

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.:  
421/60/10

Serial No.:  
10/663,879

List of Documents Cited by Applicant

Applicant(s): Tidwell et al.

Filing Date: September 16, 2003

Group:

### U.S. PATENT DOCUMENTS


Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
	1.	5,428,051	6/27/1995	Tidwell et al.	514	394	
	2.	5,574,059	11/12/1996	Regunathan et al.	514	397	
	3.	5,602,172	2/11/1997	Boykin et al.	514	461	
	4.	5,627,184	5/6/1997	Boykin et al.	514	256	
	5.	5,639,755	6/17/1997	Dykstra et al.	514	256	
	6.	5,643,935	7/1/1997	Dykstra et al.	514	394	
	7.	5,668,167	9/16/1997	Tidwell et al.	514	411	
	8.	5,686,477	11/11/1997	Jarry et al.	514	377	
	9.	5,723,495	3/3/1998	Hall et al.	514	633	
	10.	5,726,197	3/10/1998	Clark et al.	514	387	

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	11.	D. H. Wood et al., <i>Pentamidine is a Potent Inhibitor of Radioligand Binding to Imidazoline Receptors</i> , <u>Abstracts of Interscience Conf. on Antimicrobial Agents and Chemotherapy</u> 37:280 (1997).
--	-----	--



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: 421/60/10	Serial No.: 10/663,879
List of Documents Cited by Applicant		Applicant(s): Tidwell et al.	
		Filing Date: September 16, 2003	Group:
	12.	M. Pigni et al., <i>Imidazoline Receptors: Qualitative Structure-Activity Relationships and Discovery of Tracizonline and Benazonline. Two Ligands with High Affinity and Unprecedented Selectivity</i> , <u>Bio. &amp; Med. Chem.</u> <b>5(5)</b> :833-841 (1997).	
	13.	D. H. Wood et al., <i>1,5-Bis(4-amidinophenoxy)pentane(pentamidine) is a Potent Inhibitor of [<sup>3</sup>H]idazoxan Binding to Imidazoline I<sub>2</sub> Binding Sites</i> , <u>Euro J. of Pharmacology</u> <b>353</b> :97-103 (1998).	
	14.	A. Carrieri et al., <i>2-D and 3-D Modeling of Imidazoline Receptor Ligands: Insights into Pharmacophore</i> , <u>Bio &amp; Med. Chem.</u> <b>5(5)</b> :843-856 (1997).	
	15.	D. H. Wood et al., <i>Pentamidine is a Potent Inhibitor of [<sup>3</sup>H]idazoxan Binding to Imidazoline I<sub>2</sub> Receptors</i> , <u>Annals New York Academy of Sciences</u> 110-113 (undated) (XP-000892876).	
	16.	B. Tao et al., <i>Novel Bisbenzamidines and Bisbenzamidazolines as Noncompetitive NMDA Receptor Antagonists</i> , <u>Bio &amp; Med. Chem. Ltrs</u> <b>9</b> :1299-1304 (1999).	
	17.	A. Yu et al., <i>Imidazoline Receptor Agonist Drugs: A New Approach to the Treatment of Systemic Hypertension</i> , <u>J. Clin. Pharmacol.</u> <b>36</b> :98-111 (1996).	
	18.	S. Regunathan et al., <i>Imidazoline Receptors and Their Endogenous Ligands</i> , <u>Annu. Rev. Pharmacol. Toxicol.</u> <b>36</b> :511-544 (1996).	
	19.	G. J. Molderings, <i>Imidazoline Receptors: Basic Knowledge, Recent Advances and Future Prospects for Therapy and Diagnosis</i> , <u>Drugs of the Future</u> <b>22(7)</b> :757-772 (1997).	
	20.	C. Farsang et al., <i>Imidazoline Receptors: From Discovery to Antihypertensive Therapy (facts and doubts)</i> , <u>Brain Res. Bulletin</u> <b>49(5)</b> :317-331 (1999).	

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.